“The use of adult stem cells derived from adipose (fat) tissue to treat congestive heart failure has the potential to change the game for the millions of patients suffering from this disease”, said Miller.
Freeport, Bahamas (PRWEB) July 17, 2013
Okyanos Heart Institute, whose mission it is to bring a new standard of care and better quality of life to patients with coronary artery disease using cardiac stem cell therapy, has named Leslie Miller, M.D., F.A.C.C. as its chief science officer. Dr. Miller is a leading heart failure specialist and experienced thought leader in cardiac stem cell therapy. He is director of the University of South Florida (USF) Heart Institute, professor of cardiovascular sciences at the USF Health Morsani College of Medicine, and was formerly the director of cardiology at Georgetown University. Dr. Miller has been an investigator in over 80 clinical trials.
“The use of adult stem cells derived from adipose (fat) tissue to treat congestive heart failure has the potential to change the game for the millions of patients suffering from this disease”, said Miller. “These stem and regenerative cells have been shown to stimulate the growth of new blood vessels, are anti-inflammatory and prevent at-risk cells from dying. These combined mechanisms can provide important therapeutic benefit to heart failure patients.”
“As a current member of Okyanos’ medical advisory council, Dr. Miller has actively advised us on patients criteria for cardiac stem cell therapy”, says Okyanos’ Chief Medical Officer Howard Walpole. “In this additional role as Chief Science Officer, he will be evaluating new research protocols and reporting on findings from the patient registry that will help advance the field of cardiac stem cell therapy. His experience and track record in leading academic research is outstanding. This integrated approach in research and clinical application in The Bahamas makes Okyanos Heart Institute one of the first places patients can receive new treatments.”
“Dr. Leslie Miller is a well-respected visionary in the field of cardiovascular disease” says Okyanos CEO Matt Feshbach. “This role will further advance our quality measures and the structure of our patient registry. We look forward to his contribution to improving the lives of patients using adult stem cells derived from their own fat tissue who, up until now, have exhausted their options with conventional treatments.”
ABOUT OKYANOS HEART INSTITUTE: (Oh – key – AH – nos)
Based in Freeport, The Bahamas, Okyanos Heart Institute’s mission is to bring a new standard of care and a better quality of life to patients with coronary artery disease using cardiac stem cell therapy. Okyanos adheres to U.S. surgical center standards and is led by Chief Medical Officer Howard T. Walpole Jr., M.D., M.B.A., F.A.C.C., F.A.C.A.I. Okyanos Treatment utilizes a unique blend of stem and regenerative cells derived from one’s own adipose (fat) tissue. The cells, when placed into the heart via a minimally-invasive catheterization, stimulates the growth of new blood vessels, a process known as angiogenesis. The treatment facilitates blood flow in the heart and supports intake and use of oxygen (as demonstrated in rigorous clinical trials such as the PRECISE trial). The literary name Okyanos (“Oceanos”) symbolizes flow. For more information, go to http://www.okyanos.com/.
NEW MEDIA CONTENT:
Okyanos LinkedIn page:
Okyanos Facebook page:
Okyanos Twitter page: